Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04242238 · ClinicalTrials.gov registry record · Phase 1
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT04242238: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04242238 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04242238, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study is being done to find the safest dose of DCC-3014 that can be given with avelumab to participants with advanced or metastatic sarcomas that will not cause serious side effects.
Interventions
- DRUG Avelumab
- DRUG DCC-3014
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-01-22 |
| Est. Completion | 2025-08-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04242238
The ClinicalTrials.gov registry entry for NCT04242238 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Avelumab is the first listed.
NCT04242238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04242238 about?
NCT04242238 is a clinical study titled "Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas". This study is being done to find the safest dose of DCC-3014 that can be given with avelumab to participants with advanced or metastatic sarcomas that will not cause serious side effects.
What is the current status of trial NCT04242238?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2020-01-22. Estimated completion is 2025-08-26.
What interventions are being tested in trial NCT04242238?
The interventions under investigation include: Avelumab (DRUG), DCC-3014 (DRUG).
Who is sponsoring clinical trial NCT04242238?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.